tradingkey.logo

Pluri Inc

PLUR
查看详细走势图
3.460USD
+0.010+0.29%
收盘 12/19, 16:00美东报价延迟15分钟
28.24M总市值
亏损市盈率 TTM

Pluri Inc

3.460
+0.010+0.29%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+0.29%

5天

+12.34%

1月

-11.28%

6月

-12.66%

今年开始到现在

-19.06%

1年

-28.22%

查看详细走势图

TradingKey Pluri Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Pluri Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名169/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价12.00。中期看,股价处于下降通道。近一个月,市场表现较差,但技术面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Pluri Inc评分

相关信息

行业排名
169 / 404
全市场排名
300 / 4582
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 1 位分析师
买入
评级
12.000
目标均价
+283.39%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Pluri Inc亮点

亮点风险
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
业绩高增长
公司营业收入稳步增长,连续3年增长365.51%
业绩增长期
公司处于发展阶段,最新年度总收入1.34M美元
估值合理
公司最新PE估值-1.08,处于3年历史合理位
机构加仓
最新机构持股1.60M股,环比增加1.49%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值33.92K
活跃度降低
近期活跃度降低,过去20天平均换手率-0.76

Pluri Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Pluri Inc简介

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
公司代码PLUR
公司Pluri Inc
CEOYanay (Yaky)
网址https://pluri-biotech.com/

常见问题

Pluri Inc(PLUR)的当前股价是多少?

Pluri Inc(PLUR)的当前股价是 3.460。

Pluri Inc的股票代码是什么?

Pluri Inc的股票代码是PLUR。

Pluri Inc股票的52周最高点是多少?

Pluri Inc股票的52周最高点是7.130。

Pluri Inc股票的52周最低点是多少?

Pluri Inc股票的52周最低点是2.820。

Pluri Inc的市值是多少?

Pluri Inc的市值是28.24M。

Pluri Inc的净利润是多少?

Pluri Inc的净利润为-22.58M。

现在Pluri Inc(PLUR)的股票是买入、持有还是卖出?

根据分析师评级,Pluri Inc(PLUR)的总体评级为买入,目标价格为12.000。

Pluri Inc(PLUR)股票的每股收益(EPS TTM)是多少

Pluri Inc(PLUR)股票的每股收益(EPS TTM)是-3.137。
KeyAI